(Q36414904)

14 August 2017

1 reference

title

Low-molecular-weight heparins and angiogenesis (English)

1 reference

14 August 2017

Klas Norrby

1

1 reference

14 August 2017

language of work or name

1 reference

1 February 2006

1 reference

Acta Pathologica et Microbiologica Scandinavica

14 August 2017

published in

1 reference

14 August 2017

volume

114

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

79-102

1 reference

Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Low-molecular-weight heparin in thrombosis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Interfering with hemostatic system components: possible new approaches to antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

The heparins and cancer: review of clinical trials and biological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Therapeutic uses of heparin beyond its traditional role as an anticoagulant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Heparin-mediated selective release of hepatocyte growth factor in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

The effects of high molecular weight- and low molecular weight-heparins on superoxide ion production and degranulation by human polymorphonuclear leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Redox signaling in vascular angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Generic low-molecular-weight heparins: some practical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Pharmacokinetics of UH and LMWH are similar with respect to antithrombin activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Identification of a heparin-binding protein using monoclonal antibodies that block heparin binding to porcine aortic endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Heparin regulates transcription of endothelin-1 gene in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Antitumor and antimetastatic effect of warfarin and heparins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Low-molecular-weight heparin and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Antimetastatic effect of tinzaparin, a low-molecular-weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Effect of low molecular weight heparin on intra-abdominal metastasis in a laparoscopic experimental study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

The effect of low molecular weight heparin on survival in patients with advanced malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Heparin reverses Rhodamine 123 extrusion by multidrug resistant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Anticoagulant drugs increase natural killer cell activity in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Thrombin signalling and protease-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Thrombin induces neoangiogenesis in the chick chorioallantoic membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Thrombosis increases circulatory hepatocyte growth factor by degranulation of mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Mast cells and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Roles of hepatocyte growth factor and mast cells in thrombosis and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Platelet factor 4: an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Regulation of angiogenesis by tissue factor cytoplasmic domain signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Heparin, monocytes, and procoagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Heparanase induces endothelial cell migration via protein kinase B/Akt activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Microvascular density in terms of number and length of microvessel segments per unit tissue volume in mammalian angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Chemotherapy and antiangiogenesis: drug-specific effects on microvessel sprouting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Tumor angiogenesis: past, present and the near future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Variations in the Size and Sulfation of Heparin Modulate the Effect of Heparin on the Binding of VEGF165 to Its Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Low molecular weight fucoidan and heparin enhance the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfate-dependent alpha6 overexpression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

In vivo treatment of rats with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) does not affect experimentally induced colon carcinoma metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Undersulfated and glycol-split heparins endowed with antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Heparin derivatives as angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Low- and ultra-low-molecular-weight heparins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Human apo-lactoferrin enhances angiogenesis mediated by vascular endothelial growth factor A in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Cell surface glypicans are low-affinity endostatin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

Endostatin Associates with Lipid Rafts and Induces Reorganization of the Actin Cytoskeleton via Down-regulation of RhoA Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

The MET oncogene drives a genetic programme linking cancer to haemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0463.2006.APM_235.X

10.1111/J.1600-0463.2006.APM_235.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference